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Abstract: Non-enzymatic protein glycosylation (glycation) contributes to many diseases 
and aging of organisms. It can be expected that inhibition of glycation may prolong the 
lifespan. The search for inhibitors of glycation, mainly using in vitro models, has identified 
natural compounds able to prevent glycation, especially polyphenols and other natural 
antioxidants. Extrapolation of results of in vitro studies on the in vivo situation is not 
straightforward due to differences in the conditions and mechanism of glycation, and 
bioavailability problems. Nevertheless, available data allow to postulate that enrichment of 
diet in natural anti-glycating agents may attenuate glycation and, in consequence, ageing. 
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1. Glycation 
Louis Camille Maillard (1912) first reported that reducing sugars react with amino acids in solution 
producing dark-colored products (melanoidins) [1]. Similar chemical reactions could be observed also 
in solutions of reducing sugars mixed with peptides and proteins. This reaction, called now the “Maillard 
reaction”, is a complex network of successive and parallel reactions. Initially,a sugar having the 
functionality of the aldehyde group, or an aldehyde, reacts non-enzymatically with a thiol or amino 
groups of a protein (or another biomolecule) forming a Schiff base. Comparison of reactivity of various 
amino acid residues in peptides with reducing sugars revealed the highest reactivity of side chains of 
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cysteine, lysine, and histidine, and amino groups of the N-terminal amino acids [2]. The Schiff bases 
rearrange over a period of days to produce ketoamine or Amadori products. The Amadori products 
undergo dehydration and rearrangements followed by other reactions such as cyclisation, oxidation, and 
dehydration to form more stable Advanced Glycation End Products (AGEs) [3]. Dicarbonyl products, 
glyoxal and methylglyoxal, formed as intermediate products in the course of the Maillard reaction, are 
of great importance. These highly active compounds, which are also formed in the cell as by-products 
of glycolysis, can react with proteins producing cross-links resistant to the action of enzymes. 
Carboxymethyl-lysine (CML), a non-fluorescent protein adduct, was first described by Ahmed and 
represents the most prevalent AGE in vivo [4]. Pentosidine (a fluorescent glycoxidation product) was 
first isolated and characterized by Sell and Monnier [5]. Other AGEs identified in vivo include 
glucosepane, carboxymethyl-hydroxylysine, carboxyethyllysine (CEL), fructose-lysine, and pyrraline, 
which form non-fluorescent protein adducts, fluorescent methylglyoxal-derived hydroimidazolone 
(MGH1), which contributes significantly to skin fluorescence [6], and glyoxal-lysine dimer and 
methylglyoxal-lysine dimer forming non-fluorescent protein crosslinks [7]. Glycation alters the structure 
and functional properties of proteins, which affects adversely cellular metabolism. 
AGE formation takes place under normal physiologic conditions but is accelerated in  
hyperglycemia [8–10]. AGEs may also form from non-glucose sources including lipid and amino acid 
oxidation [9,11,12]. Increased level of reactive oxygen species (ROS) cause oxidative stress; in analogy, 
increased concentration of sugars (glucose, deoxyglucose, fructose, ribose and triose phosphates) and 
active dicarbonyl compounds (glyoxal and methylglyoxal) can cause “carbonyl stress” resulting in the 
increased rate of formation of AGEs.  
Among all the natural monosaccharides, glucose is characterized by the maximal shift of the 
equilibrium between the cyclic and aldehyde isoforms (only 0.2% existing in the aldehyde form). Thus, 
glucose is one of the least active sugars in relation to glycation and this property might have been the 
reason for the evolutionary choice of glucose as the universal carbohydrate energy carrier [13].  
AGEs accumulate intracellularly mainly because of their generation from glucose-derived dicarbonyl 
precursors formed in the course of metabolism [14,15]. Although it is possible that intracellular AGEs 
can play positive roles as stimuli for activating intracellular signaling pathways and modifying the 
function of intracellular proteins, there is a plethora of evidence that their accumulation adversely affects 
protein structure and function. Cytoskeletal proteins are important in providing stability of the 
cytoskeleton and are crucially involved in numerous cellular functions such as migration and cellular 
division. Various other intracellular proteins including enzymes and growth factors may be targets of 
non-enzymatic modification by sugars. Glycated basic fibroblast growth factor (bFGF) displays 
impaired mitogenic activity in endothelial cells [14]. Glycation of enzymes of the ubiquitin-proteasome 
system and of the lysosomal proteolytic system has been shown to inhibit their action [16]. The structural 
components of the connective tissue matrix and basement membrane components (e.g., type IV collagen) 
as well as other long-lived proteins (including myelin, tubulin, plasminogen activator 1 and fibrinogen) 
can also undergo advanced glycation [17]. It should be mentioned that AGE-modified proteins may be 
more resistant to enzymatic degradation [18]. 
Accumulation of glycation products is associated with various diseases including, first of all, diabetes 
and diabetic nephropathy, microangiopathy and atherosclerosis [12]. Indeed, the intermolecular collagen 
cross-linking caused by AGEs leads to diminished arterial and myocardial compliance and increased 
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vascular stiffness, phenomena that are considered to explain partly the increase in diastolic dysfunction 
and systolic hypertension seen in diabetic patients [19]. Yuen et al. (2010) suggested that collagen 
glycation augments the formation and migration of myofibroblasts and participates in the development 
of fibrosis in diabetes [20]. Other studies showed that glycated collagen alters the endothelial cell 
function and could be an important factor in atherosclerotic plaque development [21]. More recently, it 
was revealed that AGEs may act as mediators of the progression of stable to rupture-prone plaques; this 
finding opens a window towards biomarkers and novel treatments of cardiovascular diseases [22].  
A significant effect of AGEs involves their interactions with receptors (receptors for AGEs or RAGEs 
and others). Interaction of AGEs with RAGEs generates secondary oxidative stress and plethora of other 
undesired effects including increased gene transcription of pro-inflammatory and pro-fibrotic cytokines 
and chemokines leading to an inflammatory condition [23], which, in turn, in many instances, promotes 
epithelial cell malignant transformation, contributing to tumorigenesis [24]. Shortened RAGEs 
(sRAGEs) circulating in blood and body fluids, which lack the transmembrane domain, include an 
endogenous secretory isoform generated via alternative splicing and a form generated through 
proteolytic cleavage of the full-length cell surface receptor, serve as competitive binding sites for AGEs 
diminishing their effects on RAGEs [12]. 
There is a relationship between activation of the AGE-RAGE system and some aspects of polycystic 
ovary syndrome (PCOS), such as granulosa cell dysfunction, adipocyte pathophysiology, obesity and 
insulin resistance. Furthermore, irregular ovarian AGE signaling might in part explain the abnormal 
ovarian histology observed in women with PCOS [25].  
The serum level of AGEs has been found to be elevated in such diseases as cystic fibrosis [26],  
non-B or non-C hepatocellular carcinoma [27], relapsing-remitting multiple sclerosis [28,29] or 
schizophrenia [30]. It should be mentioned that glycation induces refolding of initially globular albumin 
into amyloid fibrils comprising cross-β structure [31]. Moreover, glycation induces the formation of the 
β-sheet structure in β-amyloid protein, β-synuclein, transthyretin, as well as copper–zinc superoxide 
dismutase. Aggregation of the β-sheet structure in the brain creates fibrillar structures, respectively 
causing Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, familial amyloid 
polyneuropathy and prion disease. It has been also suggested that oligomeric species of glycated  
α-synuclein and prion are more toxic than fibrils [32].  
A controversy remains regarding the content of AGEs as a biochemical marker of Alzheimer’s 
disease. Thome and co-workers (1996) examined the question whether the reported increased level of 
AGEs in the brain is reflected in an increase in AGE-associated parameters in peripheral blood [33]. 
These authors reported that elevated central nervous system AGEs levels in patients with Alzheimer’s 
disease are manifested without detectable peripheral changes, however other investigators demonstrated 
moderate increases in Amadori products of plasma proteins [34]. A more recent study revealed a lower 
level of circulating serum AGEs in patients with Alzheimer’s disease in relation to healthy controls [35]. 
In addition, literature data indicate that accumulation of AGEs plays an important role in the 
development of degenerative changes in the lens of the eye, leading to blindness or cataract. Progression 
of cataract is increased in patients with diabetes mellitus [36]. AGEs induce irreversible structural 
changes in the protein, resulting in the formation of protein aggregates of high molecular weight, which 
impede vision and light scatter [37]. It has been shown that AGEs, by altering the surface charge of the 
protein, lead to conformational changes and consequently reduces the transparency of the lens of the  
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eye [38]. AGEs also play an important role in the progression of diabetic retinopathy leading to 
dysfunction or death of retinal cells [39]. Recent reports indicate that detoxification of methylglyoxal 
reduces the accumulation of AGEs, which in turn can prevent the pathological changes in the retina and 
vessels [40].  
2. Glycation and Ageing  
Glycation has been repetitively proposed to contribute to the process of ageing. Accumulation of 
products of protein glycation with ageing has been observed [8,41]. In the early 1980s, after AGEs had 
been found to accumulate with age in tissues of living organisms, a theory of “non-enzymatic 
glycosylation as the cause of ageing” was proposed [42]. Many age-related deteriorative changes are 
actually due to protein degradation, such as posttranslational modification, accumulation of molecular 
waste, deterioration of functional proteins, functional disorders of the tricarboxylic acid cycle, or 
activation of inflammatory pathways by intracellular signals. All of these changes are symptomatic of 
“glycation stress” [43]. AGEs are metabolized by protease and oxidized protein degradation enzymes, 
such as oxidized protein hydrolase, in the proteasome and then excreted [44]. Other enzymes are also 
known to modify AGEs and intermediate compounds. For example, glyoxalase 1 is the key enzyme that 
converts the highly reactive α-oxo-aldehydes into the corresponding α-hydroxy acids using L-glutathione 
as a cofactor. Unfortunately, the activity of proteolytic enzymes decreases with age [41,45]. Most recent 
studies revealed that AGEs are mitogenic compounds and trigger cell cycle reentry of neurons in 
Alzheimer’s disease brain. The reduction of oxidative stress by application of α-lipoic acid decreased 
AGEs accumulations, and this decrease was accompanied by a reduction in cell cycle reentry and a more 
euploid neuronal genome [46].  
Galactose is much more effective than glucose as a glycating agent amount of aldehyde for many 
times exceeds that of glucose [47]. Addition of galactose to the diet was shown to cause typical 
premature ageing, in which the mitochondrial path of apoptosis involving cytochrome c release from 
mitochondria plays an important role [48]. This effect was attenuated by salidroside, an inhibitor of 
RAGE-type receptors [49]. Metformin, inhibiting AGEs formation from monosaccharides, is also 
known to be a geroprotector [2]. 
At the cellular level, aminoguanidine was shown to increase the replicative lifespan of human lung 
fibroblasts from 54 up to 75 population doublings (at 4 mM aminoguanidine) and decreased the rate of 
telomere shortening by more than 50%. While several mechanisms can contribute to this effect, the 
inhibition of glycation may be significant [50]. It has been postulated that accumulation of AGEs is the 
basis of “biological clock” governing ontogenesis and ageing [2]. 
Ageing is associated with a chronic low-grade inflammatory status that contributes to chronic diseases 
such as age-related muscle wasting, kidney disease, and diabetes mellitus. AGEs are known to be 
proinflammatory. Intervention studies in humans showed mainly a decrease in inflammation in subjects 
on a low-AGE diet, while an increase in inflammation in subjects on a high-AGE diet was less  
apparent [51]. About half of the observational studies found a relationship between inflammatory 
processes and AGEs in food. The dietary intake of AGEs appears to be related to inflammatory status 
and the level of circulating AGEs. Limiting AGE intake may lead to a decrease in inflammation and 
chronic diseases related to inflammatory status [51]. Moreover, lowering the content of AGEs in the 
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normal diet significantly prevents AGEs accumulation, attenuates oxidative stress and extends lifespan 
in mice. In humans, short-term trials demonstrated that a low-AGEs diet reduces oxidant burden and 
inflammatory markers [8]. 
3. Inhibition of Glycation 
Preventive medicine seems to be the best approach to preventing the development of lifestyle-related 
diseases such as atherosclerosis and diabetic complications. The daily intake of AGEs inhibitors in 
natural products can play a beneficial role in preventing the pathogenesis of lifestyle-related diseases. 
Therefore, natural compounds have been screened as potential inhibitors of AGEs formation [52].  
A class of compounds is known that prevent the formation of AGEs or degrade the existing AGEs. 
Some of them have been produced and patented. They include: First of all, aminoguanidine and  
anti-type 2 diabetes drugs such as metformin and pioglitazone (patented). From among other drugs in 
use, angiotensin receptor blockers, inhibitors of angiotensin converting enzyme, and pentoxyfylline 
(patented) were also found to inhibit AGE formation. Other inhibitors of protein glycation include 
antioxidants, such as vitamin C and vitamin E, and metal ion chelators (desferoxamine and 
penicillamine). Aspirin inhibits glycation competitively by capping amino groups. Amadori products 
already formed may be deglycated by enzymes called amadoriases. A group of compounds has been 
discovered, which break α-dicarbonyl cross-links, among them phenacylthiazolium bromide and its 
stable derivative ALT-711 (Alagebrium). Finally, derivatives of aryl ureido and aryl carboxaminido 
phenoxy isobutyric acids (patented) protect against glycation. Some of these compounds such as 
metformin, pioglitazone, pentoxyfylline and aspirin have already been used in clinical practice, some 
(aminoguanidine and ALT-711) have been tested in clinical trials [53].  
Aminoguanidine was the first AGEs inhibitor discovered in 1986; its mechanism of action involves 
catching reactive intermediates generated by the Maillard reaction. Animal models of type 1 and 2 
diabetes showed that aminoguanidine prevents formation of AGEs and thus diabetic complications, 
including vascular ones [54]. Aminoguanidine half-life in plasma is short (about 1 h), therefore, it must 
be applied at a relatively high dose (1 g/L of water) to produce a concentration sufficient to trap reactive 
species [55]. The use of high concentrations of aminoguanidine is not preferred because of its reaction 
with vitamin B6, which in turn causes a deficiency. Another inhibitor of AGE formation is pyridoxine; 
its mechanism of action involves blocking the oxidation of compounds formed by the Maillard reaction, 
catching of reactive oxygen species and reactive carbonyl and dicarbonyl compounds or metal chelates 
which catalyze the oxidation reactions [56]. Just as aminoguanidine, pyridoxine exhibits inhibitory  
effect of vascular diseases associated with diabetes, in addition to lowering cholesterol and triglyceride 
levels [57]. Among other substances acting on the basis of catching reactive carbonyl compounds  
2,3-diaminophenazine and penicillamine should be mentioned. However, to date, there are no studies  
in vivo identifying the reaction products of these substances with the compounds produced during the 
process of glycation. Thiamine and benfotiamine one have also been described as inhibitors of the 
formation of AGEs, but their action is limited [58]. Based on the structure of thiamine and benfotiamine 
one can speculate that they may be effective metal chelators. It seems that research should focus on the 
selection of those substances that are both inhibitors of AGEs and will chelate metal ions effectively, are 
nontoxic, and their half-life in vivo is quite long. 
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There is a big interest in the search of compounds of natural origin which can inhibit glycation, apart 
from those already mentioned. Search for such compounds is based, in the first stage, on in vitro 
screening experiments. However, results of in vitro experiments may be misleading due to several 
reasons. Most AGEs products are formed by glycooxidative mechanisms that require oxygen and are 
catalyzed by traces of redox active transition metal ions [59,60]. In vitro assays for AGE formation and 
inhibition cannot adequately mimic the metal ion distribution or antioxidant and detoxification 
mechanisms in tissues and their various compartments. Especially, the sugar concentration and oxygen 
pressure are usually much higher in the in vitro experiments than in vivo. Autooxidation of glucose 
(Wolff pathway) or Schiff bases (Namiki pathway) may dominate at high glucose in vitro but not at low 
glucose and high oxygen level in vivo [60]. 
The complex nature of the Maillard reaction makes it difficult to identify the mechanism of inhibition 
of glycation. Khalifah et al. proposed a procedure to prepare proteins rich in Amadori compounds but 
free from AGEs (“pre-glycated” albumin) to identify compounds inhibiting glycation at post-Amadori 
stage of AGE formation (amadorins). Pyridoxamine, in contrast to aminoguanidine, was found to have 
amadorin activity [60]. 
4. Inhibition of Glycation in Vitro 
The antiglycation properties of numerous medical herbs and dietary plants are of a similar [61] or 
even higher order [62,63] than that of standard inhibitor of glycoxidation - aminoguanidine. In an  
in vitro assay, methanol extracts of whole plants of Calendula officinalis and fruits of Juglans regia 
showed antiglycating activity with respect to bovine serum albumin (BSA) comparable to that of 
aminoguanidine on the weight concentration basis [61]. 16 compounds were isolated from ethyl acetate 
extracts of Erigeron annuus, 3,5-di-O-caffeoyl-epi-quinic acid being the most active inhibiting BSA 
glycation, preventing opacification of lenses and inhibiting aldose reductase [63]. Ethanol extracts of 14 
wild berries were compared for their antiglycating activity in vitro. Extract of Empetrum nigrum L. 
showed the strongest activity; the anti-glycating activity correlated with the radical scavenging  
activity of the extracts [64]. Comparison of antiglycating activity of eight anthraquinones from  
the roots of Knoxia valerianoides showed considerable activity of lucidin and 1,3,6-trihydroxy-2-
methoxymethylanthraquinone [65]. Maltol was also found to have a stronger in vitro AGE inhibiting 
activity compared with aminoguanidine [62].  
In vitro glycation assays showed that a number of polyphenols exerted inhibitory effects on the 
glycation reaction. Polyphenols are the most abundant antioxidants in our diets. The main classes of 
polyphenols are phenolic acids (mainly caffeic acid) and flavonoids (the most abundant in the diet are 
flavanols, especially catechins plus proanthocyanidins), anthocyanins and their oxidation products), 
which account for one- and two-thirds of dietary polyphenols, respectively. Polyphenols are reducing 
agents, and together with other dietary antioxidants, such as vitamin C, vitamin E and carotenoids, 
protect the body’s tissues against oxidative stress and associated pathologies such as cancers, coronary 
heart disease as well as inflammation [66]. Comparison of the anti-glycating activity in vitro of 
ethanol/water extracts of coriander, turmeric, scallion, pepper mint, onion, parsley, ginger, curry, 
scallion, pepper mint, onion and parsley leaves showed a good correlation between the anti-glycating 
and antioxidant activities of the extracts [67]. 
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Phenolic acids are the main polyphenols made by plants. These compounds have diverse functions 
and are immensely important in plant-microbe interactions/symbiosis. Adisakwattana et al. (2012) found 
that cinnamic acid and its derivatives could effectively protect BSA from fructose-mediated protein 
glycation in vitro [68]. Recent investigations suggested that cinnamic acid derivatives such as ferulic 
acid (3-methoxy-4-hydroxycinnamic acid) and isoferulic acid (3-hydroxy-4-methoxycinnamic acid), 
which are the main active components of the rhizoma of Cimicifuga heracleifolia, an anti-inflammatory 
drug used frequently in Japanese traditional medicine, are also AGEs inhibitors [69–71]. The results 
obtained by Srey et al. (2010) indicated that ferulic acid effectively inhibits CML and CEL formation in 
model food systems [72]. Silván et al. (2011) reported that ferulic acid at a final concentration of  
2.5 mg/mL exerts a clear anti-glycation effect, mainly due to an inhibition of the advanced stage of the 
glycation reaction (specific anti-AGE effect) [69]. More recently Meeprom et al. (2013) showed that 
isoferulic acid (1.25–5 mM) inhibits the formation of fluorescent AGEs and non-fluorescent AGE 
(CML) and fructosamine protein adducts [71]. It should be noted that isoferulic acid has been found to 
be a metal ion chelating agent. From this point, metal chelating activity of isoferulic acid might be one 
of possible mechanism responsible for inhibition of glycation. 
Huang et al. (2008) investigated the inhibitory abilities of phenolic acids (chlorogenic acid, syringic 
acid and vanillic acid) on methylglyoxal-induced mouse Neuro-2A neuroblastoma (Neuro-2A) cell 
apoptosis in the progression of diabetic neuropathy. The data indicated that methylglyoxal induced 
mouse Neuro-2A neuroblastoma (Neuro-2A) cell apoptosis via alternation of mitochondria membrane 
potential and Bax/Bcl-2 ratio, activation of caspase-3, and cleavage of poly (ADP-ribose) polymerase. 
Moreover, the results showed that activation of mitogen-activated protein kinase signal pathways (JNK 
and p38) participated in the methylglyoxal-induced Neuro-2A cell apoptosis process. Thus, treatment of 
Neuro-2A cells with phenolic acids suppresses cell apoptosis induced by methylglyoxal, suggesting that 
phenolic acids possess cytoprotective ability in the prevention of diabetic neuropathy complications [73]. 
Other polyphenols present in many dietary sources also have the anti-glycating activity. For example, 
ellagic acid (2,3,7,8-tetrahydroxy-chromeno[5,4,3-cde]chromene-5,10-dione) is one of the commonly 
found dietary polyphenols. Apart from the greatest sources, such as berries and pomegranate, ellagic 
acid is also present in apples, grapes, orange, guava and cumin. Ellagic acid is known to have antioxidant, 
anti-inflammatory and anticarcinogenic properties. The antiglycating action of ellagic acid seems to 
involve, apart from inhibition of a few fluorescent AGEs, predominantly inhibition of CEL through 
scavenging of the dicarbonyl compounds. Furthermore, MALDI–TOF-MS (matrix assisted laser-desorption 
ionisation–time-of-flight MS) analysis confirms inhibition of the formation of CEL on lysozyme on  
in vitro glycation by ellagic acid. Prevention of glycation-mediated β-sheet formation in hemoglobin 
and lysozyme by ellagic acid confirm its antiglycating ability [74].  
Gugliucci et al. (2009) evaluated the anti-glycation effect of some bioactive substances present in 
yerba maté (Ilex paraguariensis): 5-caffeoylquinic acid, caffeic acid and sapogenin (oleanolic acid). 
These authors suggested that chlorogenic acid and caffeic acid are the main substances responsible for 
the anti-glycation effect of maté tea [75]. Chlorogenic acid is a phenolic compound formed by the 
esterification of caffeic and quinic acids. The inhibitory effects of chlorogenic acid on AGEs formation 
and collagen cross-linking may be caused by its interactions with reactive dicarbonyl compounds, such 
as methylglyoxal. Chlorogenic acid could be expected to be beneficial in the prevention of AGEs 
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progression in patients with diabetes [76]; however, no results clinical studies with chlorogenic acid 
have been published. 
Flavonoids (a diverse class of polyphenolic compounds), have been also demonstrated to be effective 
inhibitors of glycoxidation. The inhibition of glycoxidation has been showed for various polyphenols, 
including quercetin, genistein, tannic acid and gallic acid [77–81]. Our recent study in vitro on prevention 
of BSA glycation showed that the same compounds were found to have different effects on glycoxidation 
induced by various sugars, glyoxal and methylglyoxal, which suggests caution in extrapolation from 
experiments based on one sugar to other sugars. From among the compounds tested, the most effective 
inhibitors of glycoxidation were: polyphenols, pyridoxine and 1-cyano-4-hydroxycinnamic acid. As 
standard antioxidants had a stronger effect than metal chelators, we ascribe the inhibition of BSA 
glycation by polyphenols mainly to their antioxidant rather than metal-chelating properties [82,83]. 
Xie and Chen (2013) summarized the structural features of flavonoids relevant for their anti-glycation 
activity. They concluded that: (i) The hydroxylation on both A ring and B ring improved the inhibitory 
activity on AGEs formation, while hydroxylation on C ring decreased the activity; (ii) The methylation 
generally reduced the anti-AGEs activity of flavonoids, except for the 3-O-methylation of flavonols;  
(iii) The glycosylation of hydroxyls of flavonoids tended to decrease the inhibitory activities on 
inhibiting AGEs formation, although contradictory results were also reported; (iv) Hydrogenation of the 
C2=C3 double bond of flavones slightly weakened their activities; (v) A 5,7-dihydroxy structure was 
favorable; (vi) Proanthocyanidins dimers or trimers showed a stronger inhibitory activity than catechins, 
and the glucosides of anthocyanidin had higher activities than their rutinosides; (vii) The hydroxylation 
on B ring and the methylation of stilbenes decreased the inhibitory activity; (viii) The presence of galloyl 
groups was important for the activity of catechins, and α-hydroxyl group at C-3 was much more effective 
than β-hydroxyl group at C-3; (ix) The phenolic acids with multiple hydroxyls showed strong inhibition 
of AGEs formation, and an ortho or meta dihydroxyl structure on the benzene ring was vital to the  
anti-AGEs activity of anthraquinones; (x) Both ellagic acids and ellagitannins showed potent inhibitory 
activities on AGEs formation, and hydroxylation increased the activities but methylation decreased  
them [80]. Components of animal-derived diet may also have anti-glycating properties. Carnitine was 
found to be an effective anti-glycating compound both in vitro and in vivo [84]. 
The above results suggest that consumption of a polyphenol-rich diet may attenuate protein glycation 
to some extent, and the addition of polyphenols can be useful in reducing undesired glycoxidation in 
food processing. 
5. Inhibition of Glycation in Vivo 
5.1. Reduction of AGE Intake 
Dietary AGEs constitute a significant source of AGEs in the body. AGEs formation can be rapidly 
accelerated by increasing the time and degree of exposure to heat and can be introduced into the body 
in heat-processed foods. E. g., pretzel sticks are a rich source of pentosidine and pyrraline [85]. AGEs 
are also present in the cigarette smoke, are inhaled into the alveoli, and then they are transported to blood 
stream or to lung cells where they can interact with other glycation products and contribute to protein 
glycation [86]. While detailed mechanisms of intestinal absorption of AGEs are not fully elucidated,  
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it is known, e.g., that pyrraline is absorbed by the peptide transporter hPEPT1 [87]. It has been estimated 
that ca 10% of ingested immunoreactive AGEs are transported into circulation, two-thirds of which 
remain in the body. Exogenous AGEs are incorporated covalently in tissues, and only one third is 
excreted via the kidneys [88]. A significant correlation between the amount of ingested AGEs and the 
plasma levels of these compounds was found in humans [89].  
It has been controversial whether dietary AGEs are harmful to human health, because these 
compounds are heterogeneous and only a few have been characterized. Some of the products formed 
during this intricate reaction are furfurals, pyrralines and dicarbonyl compounds such as methylglyoxal. 
The products formed in the last reaction of this process are known as melanoidins in food science. CML 
has been reported as one of the most abundant in vivo and it was one of the first to be characterized in 
foods (milk and milk products). For this reason in most studies CML is chosen as a marker of AGEs in 
foods and in vivo [90]. However, long-term consumption of AGEs in rats was found to increase the 
levels of fasting glucose, insulin and serum AGEs [91], and induced a dose-dependent increase in 
proteinuria that over time could induce renal damage [92]. In mice, reduced dietary AGEs have been 
found to attenuate insulin resistance, increase the prevention of diabetes and, in diabetic mice, reduce 
diabetic vascular and renal complications, and improve impaired wound healing [93]. 
It should be mentioned that human breast milk contains approximately 70-fold lower amounts of 
CML than commercial infant milk and breast-fed infants had significantly lower plasma CML compared 
to infants fed with commercial infant milk [94].  
Human studies demonstrated that intake of dietary AGEs by people with type 1 and 2 diabetes 
promotes the formation of pro-inflammatory mediators, leading to tissue injury [95]. Patients with 
uremia, with and without diabetes, in whom the intake of AGEs was reduced, showed reduced levels of 
inflammatory molecules such as TNF-α and high sensitivity C-reactive protein (hsCRP) [96]. In another 
study in patients with type 2 diabetes mellitus, decreasing the intake of AGEs for six weeks resulted in 
decreased levels of circulating AGEs and inflammatory markers [97]. The effects of reducing dietary 
AGEs have also been studied in nondiabetic peritoneal dialysis patients, a group that has very high AGE 
levels, and the results showed significant reduction in the levels of AGEs and C-reactive protein [96]. 
The positive effects of calorie restriction on the lifespan of various animals, especially rodents, are 
well known, though the generality of this phenomenon has been recently questioned [98]. Calorie 
restriction involves decrease in the AGE intake. It is possible that reduction in AGE consumption 
contributes significantly to the beneficial effects of calorie restriction [99]. 
All these data suggest that reduction of dietary intake of AGEs and reduction or elimination of 
smoking can contribute to lowering the level of AGEs in the body. 
5.2. Effect of Exogenous Compounds of Natural Origin 
5.2.1. Problems with Exogenous Modification of Glycation 
Prevention of glycation in vivo is not easy to achieve. Most drugs are enzyme inhibitors of receptor 
ligands and usually have half-maximal activity at nanomolar to micromolar concentrations. In contrast, 
glycation inhibitors must react stoichiometrically with low molecular mass, soluble, reactive 
intermediates of the AGE formation pathway in the presence of much higher concentrations of reactive 
Molecules 2015, 20 3318 
 
functional groups on proteins. Lysine, for example, which is a major site of chemical modification of 
proteins by AGEs, is present in plasma proteins at a concentration of nearly 50 mM. An AGE inhibitor, 
which is unlikely to achieve a concentration of even of 100 μM in plasma, should be significantly more 
reactive with intermediates of AGE formation than protein lysine and other reactive residues [100]. 
Alternatively, the inhibitor may intercept the formation of AGEs at a stage either preceding the formation 
of the reactive carbonyl intermediates or after formation of a reactive adduct with protein. At the same 
time, it must display these activities without interfering with the intermediary metabolism of aldehydes 
or ketones, or trapping coenzymes or their precursors that contain reactive aldehydes, such as pyridoxal 
phosphate and retinal [101]. Bioavailability of exogenous compounds is an important problem in dietary 
interventions. Vlassopoulos et al. (2014) carried out a systematic literature review of dietary 
interventions reporting plasma concentrations of polyphenol metabolites. High dietary polyphenol 
intake, 3-hydroxyphenylacetic acid is the most abundant phenolic acid in peripheral blood (up to  
338 μM) with concentrations of other phenolic acids ranging from 13 nM to 200 μM [102].  
5.2.2. Effects of Natural Compounds 
Pyridoxamine (1 g/L drinking water) retarded the development of renal disease, measured by 
increases in urinary albumin and total protein and plasma creatinine, in the streptozotocin (STZ)-induced 
diabetic rat and inhibited a ca 2-fold increase in CML, CEL, Maillard-type fluorescence, and 
crosslinking of skin collagen of diabetic rats, compared to non-diabetic controls, after 7 months of 
diabetes [57]. Another study employing 0.4 g/L in drinking water, inhibited modest increases (20%–25%) 
in MOLD (methylglyoxal–lysine dimer) and pentosidine concentration in plasma proteins, and also 
inhibited a nearly 3-fold increase in plasma and erythrocyte methylglyoxal concentrations [102]. 
Pyridoxamine retarded also the development of retinopathy in the STZ-diabetic rat, as measured by 
protection against pericyte loss and formation of acellular capillaries [103]. In Zucker obese (fa/fa) rats, 
pyridoxamine inhibited the increases in fluorescence, CML, and CEL in skin collagen, increase in 
malondialdehyde and hydroxynonenal, and retarded early retinopathy as judged from proteinuria and 
plasma creatinine [104]. A study of the effect of 15 natural flavonoids, stilbenes and caffeic acid 
oligomers pointed to significant inhibition by all the flavonoids tested, especially hesperidin, naringin, 
quercetin and kaempferol. Resveratrol, piceatannol, epirabdosin, lithospermic acid and lithospermic acid 
B had also anti-glycating activity similar to aminoguanidine [105]. However, polyphenols act also via 
interference with RAGE signaling; this effect may contribute to the antitumor activity of  
polyphenols [106] so the effects observed may be contributed by other mechanisms irrespective of 
inhibition of glycation. 
Anti-glycating effect may be simply due to lowering of blood glucose level; such action has been 
demonstrated, e.g., for methanolic bark extract of Albizia odoratissima Benth. [107]. 
Recently Li et al. (2014) employed a D-galactose-induced ageing rat model to investigate the 
protective effect of the saponins from Aralia taibaiensis (Araliaceae). They suggested that, by activating 
AKT/Forkhead box O3a and nuclear factor-erythroid 2-related factor 2 pathways, saponins supplementation 
increased the expression and function of their downstream antioxidants, including superoxide dismutase 
2, catalase, glutathione reductase, glutathione, glutamate-cysteine ligase, and heme oxygenase 1, at least 
in part contributing to the protection against D-galactose-induced ageing [108]. It has been also found 
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that the oral administration of Asn-Trp or carnosine (β-alanyl-L-histidine) dipeptides ameliorates 
oxidative stress and learning dysfunctions in D-galactose-induced ageing BALB/c mice [109].  
Prisila Dulcy et al. (2012) examined the neuroprotective effect of standardized Bacopa monniera 
extract (BME: BESEB CDRI-08) against the D-galactose (D-gal)-induced brain ageing in rats. These 
findings suggest that BME treatment attenuates D-gal-induced brain ageing and regulates the level of 
antioxidant enzymes, NF-E2-related factor 2 expression, and the level of serotonin, which was 
accompanied by concomitantly increased levels of the presynaptic proteins (synaptotagmin I, 
synaptophysin) and the postsynaptic proteins (Ca2+/calmodulin dependent protein kinase II) as well as 
postsynaptic density protein-95 [110]. 
The administration of 50 mg/kg per day of maltol suppressed the elevated serum levels of 
glycosylated protein, renal fluorescent AGEs, CML, receptors for AGEs and nuclear factor-kappaB p65 
in diabetic control rats, and protected against renal damage [62]. However, in another study  
500 mg/kg/day epicatechin enhanced rather than decreased the CML accumulation on the surface of 
gastric epithelial cells in streptozotocin-diabetic mice [111]. 
Examples of more detailed results of in vivo studies are shown in Table 1. 
Stem cells have various potential uses in most medical areas due to their differentiation and paracrine 
effects. Zhang et al. (2014) reported that adipose-derived stem cells (ASCs) provide a functional benefit 
by glycation suppression, antioxidation, and trophic effects in a mouse model of ageing induced by  
D-galactose. They showed that ASCs can decrease the AGE level, therefore reversing the ageing phenotype, 
which is a similar effect to that of aminoguanidine, and inhibitors of AGEs and ASCs can decrease the 
expression of senescence-associated markers such as superoxide dismutase and malondialdehyde [112]. 
5.2.3. Effects of AGE Breakers 
AGE breakers, a new class of candidate drugs targeting ageing-related cardiovascular dysfunction, 
may be useful as novel adjuvant agents to improve the efficacy of diabetic hypertension treatment. 
Experiments conducted by Zhang et al. (2014) demonstrated that 4,5-dimethyl-3-phenacylthiozolium 
chloride (alagebrium, ALT-711) significantly improves the anti-hypertensive actions of nifedipine, a 
Ca2+ channel blocker, in a rat model of streptozotocin-induced diabetic hypertension [113]. Freidja et al. 
(2014) reported that ALT-711 did not improve flow-mediated remodeling of resistance arteries in mature 
Zucker Diabetic Fatty rats but it reduced oxidative stress and consequently improved endothelium-dependent 
relaxation. On the other hand, in mature lean Zucker rats, ALT-711 improved flow-mediated remodeling 
of resistance arteries and reduced AGEs level. Thus, AGEs breaking, at least using ALT-711, could be 
a useful therapeutic tool in ameliorating diabetic complications and with the capacity to improve  
flow-mediated remodeling in non-diabetic subjects [114]. AGEs breaking and antioxidant treatment 
improves endothelium-dependent dilation without effect on flow-mediated remodeling of resistance 
arteries in old Zucker diabetic rats. Sakul et al. (2013) applied 2-ethoxycarbonyl-8-methoxy-
2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indolinium dichloride (SMe1EC2) treatment during 4 months 
to aged streptozotocin-diabetic rats. They demonstrated that AGEs and 4-hydroxy-nonenal-histidine 
levels is significantly elevated in brain, ventricle and kidney, but not in lens and liver of aged rats when 
compared with young rats. In aged diabetic rats, SMe1EC2 protected only the kidney against increase 
in AGEs. However, it is not certain whether any natural compounds can act as AGE breakers [115]. 
Molecules 2015, 20 3320 
 
Table 1. Results of chosen in vivo studies of the effects of natural compounds on glycation. 
Population Intervention Main Findings Reference 
Healthy male Sprague–Dawley 
rats (220 ± 20 g) were divided 
randomly into four groups each 
containing 10 rats: control group, 
fructose group, betanin 25 mg/kg 
per day group, and betanin 
100 mg/kg per day group. 
Fructose water solution (30%) was accessed freely, and 
betanin (betanidin 5-O-β-D-glucoside, red) (25 and  
100 mg/kg/d) was administered by intra-gastric gavage 
continuously for 60 days. 
Betanin decreased protein glycation indexed by the 
relative lower methylglyoxal/ N-carboxymethyl lysine 
(CML) level and RAGE expression, and reduced 
glycative products in BSA/fructose system. Betanin 
also antagonized oxidative stress and NF-κB 
activation, all of them may be involved in the 
antifibrotic mechanisms. Food pigments may 
neutralize adverse effects of carbohydrate, i.e., diabetes 
and related syndrome, and complementary therapy 
with betanin may prove useful in attenuating the 
development of cardiac fibrosis in diabetes. 
[116] 
Male C57 BLKS/J genetic 
background (db/db) mice and their 
non-diabetic lean littermates 
(db/m; 6-wk-old)were randomly 
divided into five groups (n = 8 
each). 
Mice were orally administered vehicle (sterile distilled 
water), metformin (300 mg/kg), and (+)-catechin (15, 30, 
and 60 mg/kg fresh preparation with sterile distilled 
water) daily at 4:00 pm, continuously for 16 weeks. 
Metformin was used as a positive antidiabetic drug, and 
db/m mice were used as non-diabetic controls. After  
4–6 h fasting at the end of the treatment period, mice 
were killed and kidney tissues were saved for further 
assays. 
(+)-Catechin might ameliorate renal dysfunction in 
diabetic mice as consequences of inhibiting AGEs 
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Table 1. Cont. 
Population Intervention Main Findings Reference 
Two-month-old male Wistar NIN 
rats with an average bodyweight of 
220 ± 17 g were used in the study. 
Animals were distributed into four 
groups (groups I–IV). Each group 
consists of six animals. 
All the animals were fed with AIN-93 diet ad libitum. 
The control (group I) rats received sham consists of 
0.1 M citrate buffer, pH 4.5 while the experimental rats 
received a single i.p injection of streptozotocin (STZ, 
35 mg/kg) in citrate buffer. Animals in group II received 
AIN-93 diet alone whereas group III animals received 
the AIN-93 diet supplemented with 3% cinnamon 
powder whereas group IV animals received AIN-93 diet 
containing 0.002% procyanidin-B2 -fraction. All the 
animals had free access to water. 
Supplementation of diabetic rats with cinnamon and 
procyanidin-B2 -fraction prevented glycation mediated 
RBC-IgG cross-links and HbA1c accumulation in 
diabetes rats. Cinnamon and procyanidin-B2 -fraction 
also inhibited the accumulation of CML, a prominent 
AGE in diabetic kidney. Cinnamon and its 
procyanidin-B2 -fraction prevented the AGE mediated 
loss of expression of glomerular podocyte proteins; 
nephrin and podocin. Inhibition of AGE by cinnamon 
and procyanidin-B2 -fraction ameliorated the diabetes 
mediated renal malfunction in rats as evidenced by 
reduced urinary albumin and creatinine. Procyanidin-
B2 from cinnamon inhibited AGE accumulation in 
diabetic rat kidney and ameliorated AGE mediated 
pathogenesis of diabetic nephropathy. 
[118] 
Male Wistar rats (200–230 g) were 
obtained from Sanzyme Ltd. 
(Hyderabad, India). The animals 
were divided into 4 groups (n = 8). 
Diabetes was induced in all the male Wistar rats  
(200–250 g) except a group of eight animals which were 
treated as naïve (group I) by intraperitoneal 
administration of STZ (45 mg/kg) dissolved in freshly 
prepared citrate buffer (pH 4.5). The animals were fasted 
for 12 h before STZ administration and supplemented 
with 10% glucose for 48 h after STZ administration. One 
week after streptozotocin administration, blood glucose 
was estimated and the animals with more than 300 
mg/dL were treated as diabetic and after a period of 6 
weeks, the animals were divided into 3 groups. Group II 
served as diabetic control where as group III and group 
IV received resveratrol (10 mg/kg) and fidarestat  
(1 mg/kg), by per oral administration respectively, for a 
period of 3 weeks. 
Resveratrol significantly improved glycaemic status 
and renal function in diabetic rats with a significant 
decrease in the formation of AGEs in the kidneys. 
[119] 
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Table 1. Cont. 
Population Intervention Main Findings Reference 
Male Wistar rats (initial weight of  
50–75 g) were obtained from 
Charles River Breeding 
Laboratories (St-Constant, Qc, 
Canada). The animals were divided 
into six groups (Ctr3, n = 10; D3,  
n = 8; PYR, n = 8; Ctrl7, n = 9; D7, 
n = 8; ALA, n = 7).  
Rats were fed a high fat diet containing rodent diet 
D12451 (45 kcal % fat, 35 kcal % carbohydrates and 
20 kcal % protein; Research Diets, New Brunswick, NJ, 
USA) ad libitum during 8 weeks, followed by a single 
dose of STZ (30 mg/kg intra-peritoneally). Four weeks 
after the injection of STZ, rats received warfarin  
(20 mg kg−1 day−1 in drinking water) and vitamin K 
(phylloquinone, 15 mg kg−1 day−1 sub-cutaneous 
injection, Spectrum Chemical, New Brunswick, NJ, 
USA) during 3 (D3), 5 (D5) and 7 (D7) weeks. To 
determine the implication of AGEs in initiating elasto-
calcinosis, a subgroup of D3 rats received pyridoxamine 
(200 mg. kg−1 day−1) in powdered chow starting the same 
day as the STZ injection (thus during 7 weeks, including 
the 3 weeks of warfarin vitamin K (WVK) treatment) to 
prevent AGEs formation (group labeled PYR). To study 
the role of AGEs later in the calcification process, 
alagebrium (10 mg. kg−1 day−1, Synvista, Montvale, NJ, 
USA) was introduced in the food 7 weeks after the STZ 
injection (after 3 weeks of WVK treatment) and rats 
studied 4 weeks later (group labeled ALA). Dosages 
were adjusted every second day according to food 
intake. Controls consisted of age-matched untreated rats 
(Ctrl3 or Ctrl7).  
Pyridoxamine (PYR) prevented AGE accumulation, 
whereas alagebrium chloride (ALT-711) induced a 
regression of AGE cross-links. PYR prevented calcium 
accumulation, while alagebrium blunted the 
progression of calcification.  
[120] 
  
Molecules 2015, 20 3323 
 
Table 1. Cont. 
Population Intervention Main Findings Reference 
Sprague Dawley (SD) rats were 
divided into five groups  
(n = 9 each). 
Diabetes was induced by a single injection of 
streptozotocin (STZ, 60 mg/kg, intraperitoneally) in rats. 
Age-matched control rats (aged 6 weeks) received an 
equal volume of vehicle (0.01 M citrate buffer, pH 4.5). 
To investigate the effects of Cassiae semen (CS) extract, 
treatment was begun one week after the onset of diabetes 
and the compound was orally administered to the rats 
once a day for 12 weeks. SD rats were divided into 
groups: (1) normal rats (N), (2) normal rats treated with 
CS (N + CS), (3) STZ-induced diabetic rats (DM), (4) 
STZ-induced diabetic rats treated with CS (DM + CS, 
100 mg/kg body weight), and (5) STZ-induced diabetic 
rats treated with aminoguanidine (AG), a positive control 
for AGEs inhibitor (DM + AG, 100 mg/kg body weight). 
Oral treatment of CS can inhibit the development of 
diabetic nephropathy via inhibition of AGEs 
accumulation in STZ-induced diabetic rats  
The CS-treated group had significantly inhibited  
COX-2 mRNA and protein, which mediates the 
symptoms of inflammation in the renal cortex of 
diabetic rats. Histopathological studies of kidney tissue 
showed that in diabetic rats, AGEs, the receptor for 
AGEs, TGF-β1, and collagen IV were suppressed by 
CS treatment. 
[121] 
In vivo experiments were 
performed on 6-week-old male 
Wistar albino rats weighing  
180–200 g. The animals were 
divided into 12 groups, each 
containing six animals, and each 
test sample was given to two 
groups of rats. 
The control and all test groups were orally fed with 
galactose at a dose of 10 mg/kg body weight. Boswellic 
acid, corsolic acid, ellagic acid ursolic acid and quercetin 
were given at a dose of 10 mg/kg body weight. All the 
animals were sacrificed on the 15th day by spinal  
nerve dislocation. 
All the tested extracts and their active ingredients 
possess significant the polyol enzyme aldose reductase 
inhibitory actions with urosolic acid showing the most 
potent effect. The study indicates the potential of the 
studied plants and their major constituents as possible 
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Table 1. Cont. 
Population Intervention Main Findings Reference 
A total of 48 male Kunming mice 
were used (four groups, 12 mice in 
each group). 
The aggregated Aβ25–35 was injected into the right lateral 
ventricle with the following coordinates: −0.5 mm 
anterior/posterior, +1.0 mm medial/lateral and −2.5 mm 
dorsal/ventral from Bregma (10 nmol in 3 μL of saline 
per injection). Sham animals were injected in an 
identical manner with the same amount of sterile saline. 
Mice were allocated to one of four groups the day after 
sterile saline or Aβ25–35 injection: sham group,  
Aβ25–35-treated group, pinocembrin 20 mg/kg group, and 
pinocembrin 40 mg/kg group. Pinocembrin was 
administered by oral gavage once a day continuously for 
8 days. The sham group and Aβ25–35-treated group 
received oral gavage in the same manner using distilled 
water containing 20% hydroxypropyl-β-cyclodextrin 
without pinocembrin. 
Pinocembrin (a flavonoid abundant in propolis), 
significantly inhibited the upregulation of RAGE 
transcripts and protein expression both in vivo and  
in vitro, and also markedly depressed the activation of 
p38 mitogen-activated protein kinase  
(MAPK)-MAPKAP kinase-2 (MK2)-heat shock 
protein 27 (HSP27) and stress-activated protein kinase 
(SAPK)/c-Jun N-terminal kinase (JNK)-c-Jun 
pathways and the downstream nuclear factor κB 
(NFκB) inflammatory response subsequent to  
Aβ-RAGE interaction.  
Pinocembrin significantly alleviated mitochondrial 
dysfunction through improving mitochondrial 
membrane potential and inhibiting mitochondrial 
oxidative stress, and regulated mitochondrion-mediated 
apoptosis by restoration of B cell lymphoma 2 (Bcl-2) 
and cytochrome c and inactivation of caspase 3 and 
caspase 9. 
[123] 
Zebrafish maintenance and 
experimental procedures were 
approved by the Committee of 
Animal Care and Use of 
Yeungnam University 
(Gyeongsan, South Korea). Each 
group (n = 70) consumed the 
designated diet (20 mg/day/fish). 
A high cholesterol (HC) diet containing 4% cholesterol 
was made by soaking tetrabit [Tetrabit Gmbh D49304; 
47.5% crude protein, 6.5% crude fat, 2.0% crude fiber, 
10.5% crude ash, containing vitamin A (29,770 IU/kg), 
vitamin D3 (1860 IU/kg), vitamin E (200 mg/kg), and 
vitamin C (137 mg/kg); (Melle, Germany)] in a solution 
of cholesterol in diethyl ether. After ether evaporation, 
HC diet was mixed with lyophilized fruit extract (a final 
concentration of 10% w/w of powder/ tetrabit). The 
animals were divided into 5 groups: normal diet (ND) 
group, high cholesterol (HC) diet group, HC + LL 
(loquat leaves) group, acai-fed group (HC + acai) and  
HC + GS (grape skin) group.
Serum glucose levels increased in the high cholesterol 
diet group, to threefold above the ND group; GS and 
LL feeding elicited the greatest reduction in  
hyperglycemia. The groups consuming acai and LL 
showed much less hepatic inflammation, as well as 
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Table 1. Cont. 
Population Intervention Main Findings Reference 
A total of 15 male inbred C57BL/6 
J mice were used (3 groups, 5 mice 
in each group). 
Diabetes was induced in the mice by a single dose of 
STZ (200 mg/kg). Mice were fed a normal rodent chow 
diet (Clea Japan) for 1 week after induction of diabetes. 
At this time, these mice were administered epicatechin  
(500 mg/kg/day) orally every day for 45 days. Animals 
were divided into groups: control group, mice treated 
with epicatechin (500 mg/kg/day), and mice treated with 
arbutin, a catechol analogue (500 mg/kg/day).  
Administration of 500 mg/kg/day epicatechin to STZ-
induced diabetic mice enhanced the CML 
accumulation on the surface of gastric epithelial cells, 
whereas administration of 500 mg/kg/day arbutin to 
STZ-induced diabetic mice did not enhance CML 
accumulation compared to untreated mice. High 
amounts of catechol-containing structures enhance 
oxidative stress, thus leading to enhanced CML 
formation, and this phenomenon may explain the 
paradoxical effect that some flavonoids have on redox 
status. 
[111] 
Adult male Wistar rats of body 
weight 150–160 g were used in the 
study. The animals were divided 
into four groups of six rats each. 
Control animals (CON) received the control diet 
containing starch and tap water ad libitum. Fructose-fed 
animals (FRU) received the high fructose diet and water 
ad libitum. Fructose-fed animals (FRU-CA) received the 
high fructose diet and water ad libitum and were 
administered 300 mg carnitine (CA)/kg b.w/day; i.p.  
Control animals (CON-CA) received the control diet and 
water ad libitum and were administered with 300 mg 
CA/kg b.w/day; i.p. 
The levels of glucose, fructose and fructosamine in 
plasma and glycated haemoglobin and methyl glyoxal 
in blood were significantly higher in fructose-fed 
animals than in the control rats. Administration of CA 
along with the fructose diet reduced these levels 
significantly. In rats fed control diet, administration of 
CA did not produce significant alterations in the 
parameters when compared with the control group. The 
rats fed fructose diet showed increased total collagen 
and glycation in tail tendon and skin as compared to 
control rats. CA-administered fructose-fed rats 
registered near-normal levels of collagen and 
glycation. No significant changes were observed in 
control rats treated with CA. 
[84] 
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6. Conclusions  
Many natural compounds, especially polyphenols, have been found to inhibit efficiently protein 
glycation in vitro. Their action in vivo is more problematic due to the bioavailability problems. 
Nevertheless, some positive effects of natural antioxidants against the consequences of excessive 
glycation have been found. While the mechanisms of their action may go beyond direct inhibition of 
glycation, there are reasons to expect that natural compounds used as food additives may prevent adverse 
effects of protein glycation and, in consequence, delay ageing. Another useful approach may consist in 
limitation of AGE intake in the food.  
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